PRODUCT MONOGRAPH

PrLEMTRADA™
álezmtuzumab
12 mg/1.2 mL
Concentrate for solution for intravenous infusion
Therapeutic Classification: Selective Immunomodulator

Treatment with LEMTRADA should be initiated and supervised by neurologists experienced in the treatment of patients with MS and who have fully familiarised themselves with the efficacy and safety profile of PrLEMTRADA™

Genzyme Canada, a division of sanofi-aventis Canada Inc.  
800 – 2700 Matheson Blvd. East, West Tower 
Mississauga, ON 
L4W 4V9 
www.genzyme.ca

Date of Authorisation 
December 12, 2013

Submission Control No: 161152
LEMTRADA™ is a trademark of Genzyme Corporation

LEMTTRAĐADA™ (álezmtuzumab) Product Monograph
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION

- SUMMARY PRODUCT INFORMATION
- INDICATIONS AND CLINICAL USE
- CONTRAINDICATIONS
- WARNINGS AND PRECAUTIONS
- ADVERSE REACTIONS
- DRUG INTERACTIONS
- DOSAGE AND ADMINISTRATION
- OVERDOSAGE
- ACTION AND CLINICAL PHARMACOLOGY
- STORAGE AND STABILITY
- DOSAGE FORMS, COMPOSITION AND PACKAGING

PART II: SCIENTIFIC INFORMATION

- PHARMACEUTICAL INFORMATION
- CLINICAL TRIALS
- DETAILED PHARMACOLOGY
- TOXICOLOGY
- REFERENCES

PART III: CONSUMER INFORMATION
PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous (IV)</td>
<td>Single use vial containing 12 mg in 1.2 mL (10 mg alemtuzumab/mL)</td>
<td>sodium chloride, dibasic sodium phosphate, potassium chloride, potassium dihydrogen phosphate, polysorbate 80, disodium edetate dihydrate, water for injection</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

LEMTTRA™ (alemtuzumab) is indicated for the management of adult patients with relapsing remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

LEMTTRA™ treatment should be initiated and supervised by neurologists experienced in the treatment of patients with MS and who have fully familiarized themselves with the efficacy and safety profile of LEMTRA™ (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION sections).

Specific pre-medication should be administered before injecting LEMTRA™ (see DOSAGE AND ADMINISTRATION).

Resources for the treatment of anaphylactic reactions should be immediately available.

Patients treated with LEMTRADA must be given the ‘Patient Alert Card’, ‘Patient Guide’ and package leaflet, and be informed about the risks of LEMTRADA.

Safety and efficacy in patients with chronic progressive multiple sclerosis, and in geriatric or pediatric patients, have not been established.
The efficacy of LEMTRADA for treatment duration beyond 2 years has not been determined.

**Geriatrics (≥ 65 years of age):**
Clinical studies of LEMTRADA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients (see WARNINGS AND PRECAUTIONS, Special Populations).

**Pediatrics (< 18 years of age):**
The safety and efficacy of LEMTRADA in pediatric MS patients below the age of 18 years of age have not been established (see WARNINGS AND PRECAUTIONS, Special Populations).

**CONTRAINDICATIONS**

LEMTTRAĐA is contraindicated in:
- Patients who are hypersensitive to alemtuzumab or to any ingredient in the formulation or component of the container. For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING.
- Patients who are infected with Human Immunodeficiency Virus (HIV)
- Patients who have active or latent tuberculosis (see WARNINGS AND PRECAUTIONS, Infections)
- Patients who have severe active infections (see WARNINGS AND PRECAUTIONS, Infections).
- Patients with active malignancies.
- Patients on antineoplastic or immunosuppressive therapies.
- Patients with a history of progressive multifocal leukoencephalopathy (PML)
WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- **Autoimmunity:** Serious, including fatal, autoimmune conditions such as immune thrombocytopenic purpura and anti-glomerular basement membrane disease can occur in patients receiving LEMTRADA. Complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts should be monitored at monthly intervals in patients who have received LEMTRADA.

- **Infections, including Opportunistic Infections:** Serious and sometimes fatal viral, bacterial, protozoan, and fungal infections, including those due to reactivation of latent infections, have been reported in non-MS patients treated with alemtuzumab at higher and more frequent doses than used in MS. Physicians should consider delaying initiation of LEMTRADA administration in patients with active infection until the infection is fully controlled. Anti-viral prophylaxis is strongly recommended. (See WARNINGS AND PRECAUTIONS: Infections)
  - Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus which causes serious disability or death (see WARNINGS AND PRECAUTIONS, Infections; CONTRAINDICATIONS; ADVERSE REACTIONS). PML has been reported in patients with B-CLL with or without treatment with alemtuzumab, and in patients with multiple sclerosis treated with certain immunosuppressants. The frequency of PML in B-CLL patients treated with MabCampath is no greater than the background frequency. Therefore, healthcare professionals should monitor patients on LEMTRADA for any new sign or symptom suggestive of PML. LEMTRADA dosing should be withheld immediately at the first sign or symptom suggestive of PML.

**General**

Before initiating treatment with LEMTRADA™ (alemtuzumab):
- All patients must be evaluated for both active and inactive (“latent”) tuberculosis infection, according to local guidelines.
- All patients must be evaluated for HBV and HCV.
- Sexually active female patients should be screened annually for HPV.
- Due to the risk of developing Lemtrada-induced autoimmune thyroid disease, thyroid form and function should be closely monitored for early intervention.
- To assist in the differential diagnosis for PML, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain is recommended (see WARNINGS AND PRECAUTIONS, Infections).
- Specific pre-medication should be provided prior to LEMTRADA administration, including prophylaxis with an oral anti-herpes agent (see DOSAGE AND ADMINISTRATION).
- Immunization should be completed at least 6 weeks prior to treatment with LEMTRADA (seeWARNINGS AND PRECAUTIONS, Immunization).
LEMTRADA™ (alemtuzumab) Product Monograph  Page 6 of 39

LEMTRADA is not recommended for patients with inactive disease or those stable on current therapy. Patients treated with LEMTRADA must be given the Patient Alert Card, the Patient Guide and the Package Leaflet. Before treatment, patients must be informed about the risks and benefits and the need to commit to at least 48 months of follow-up after the last infusion of LEMTRADA.

**Infusion Associated Reactions:**
In clinical trials, infusion associated reactions (IARs) were defined as any adverse event occurring during or within 24 hours of LEMTRADA infusion. 82% of patients treated with LEMTRADA in controlled clinical trials in MS experienced mild to moderate IARs during and/or up to 24 hours after LEMTRADA 12 mg administration despite precautionary treatment with corticosteroids, and 9% of patients experienced severe IARs. IARs included headache (43.7%), rash (43.1%), pyrexia (25.2%), nausea (15.9%), urticaria (14.7%), pruritus (12.7%), insomnia (11.1%), chills (9.5%), flushing (9.5%), fatigue (8.4%), dyspnea (7.2%), dysgeusia (7.0%), chest discomfort (6.6%), generalized rash (6.5%), tachycardia (6.4%), dyspepsia (6.2%), dizziness (5.7%), and pain (5.2%). Serious reactions occurred in 3% (26/919) of patients and included cases of cardiac arrhythmias (tachycardia, bradycardia and atrial fibrillation), pyrexia, urticaria, nausea, chest discomfort, and hypotension. In the follow-up study, anaphylaxis has been reported rarely. Patients in controlled clinical trials commonly received antihistamines and/or antipyretics to prevent or treat infusion associated reactions.

An EKG should be done and assessed before each treatment course.

Patients should be premedicated with corticosteroids immediately prior to the initiation of the LEMTRADA infusion for the first 3 days of any treatment course to ameliorate the effects of infusion reactions (see DOSAGE AND ADMINISTRATION section). In clinical trials patients were pretreated with 1,000 mg of methylprednisolone for the first 3 days of each LEMTRADA treatment course. Pretreatment with antihistamines and/or antipyretics prior to LEMTRADA administration may also be considered. Most patients in controlled clinical trials received antihistamines and/or antipyretics before at least 1 LEMTRADA infusion. IARs may occur in patients despite pretreatment. Active observation for infusion-associated reactions in the clinic is recommended during and for at least 2 hours after each LEMTRADA infusion, or longer at the discretion of the physician. Patients should be educated to look for signs and symptoms of infusion associated reactions particularly for the first 24 hours after each LEMTRADA infusion. If an IAR occurs, provide the appropriate symptomatic treatment, as needed. If the infusion is not well tolerated, the infusion duration may be extended. If severe infusion reactions occur, immediate discontinuation of the IV infusion should be considered. Physicians should be familiar with the patient’s cardiac history, since infusion-associated reactions can include cardiac symptoms such as tachycardia.

Resources for the treatment of anaphylaxis should be immediately available.

**Carcinogenesis and Mutagenesis**
There have been no studies to assess the carcinogenic or mutagenic potential of alemtuzumab.
However, 13/1485 (0.88%) patients reported a total of 15 malignancies in the alemtuzumab pooled dose group over all available follow-up (6 patients in the 12 mg/day group, 7 patients in the 24 mg/day group). The most common malignancies reported in more than 1 alemtuzumab-treated patient were thyroid cancer, breast cancer, and basal cell carcinoma. Of the 15 reported events of malignancy, 8 were assessed as being related to treatment with LEMTRADA by the investigator. As with other immunomodulatory therapies, caution should be exercised in initiating LEMTRADA therapy in patients with pre-existing malignancy. Treatment with LEMTRADA is contraindicated in patients with active malignancies.

**Immune**

**Autoimmunity**
Treatment with LEMTRADA may result in the formation of autoantibodies and increase the risk of autoimmune mediated conditions including immune thrombocytopenic purpura (ITP), thyroid disorders or, rarely, nephropathies (e.g., anti-glomerular basement membrane disease). Caution should be exercised in patients with a history of autoimmune conditions (in addition to MS).

**Immune Thrombocytopenic Purpura:**
Serious events of ITP have been observed in approximately 1% (10/1188) of patients treated with LEMTRADA in controlled clinical trials in MS. In a controlled clinical trial in patients with MS, 1 patient developed ITP that went unrecognized prior to the implementation of monthly blood monitoring requirements and died from intracerebral hemorrhage. ITP onset has occurred between 14 and 36 months after first LEMTRADA exposure. Symptoms of ITP include easy bruising, petechiae, spontaneous mucocutaneous bleeding (e.g., epistaxis, haemoptysis), and heavier or irregular menstrual bleeding. Haemoptysis may also be indicative of anti-GBM disease (see below). Remind the patient to remain vigilant and to seek immediate medical help for any concerns. Complete blood counts (CBC) with differential should be obtained prior to initiation of treatment and at monthly intervals thereafter until 48 months after the last infusion. If ITP is suspected a CBC should be obtained immediately. If ITP onset is confirmed, appropriate medical intervention should be promptly initiated, including referral to a specialist. Data from clinical trials in MS has shown that adherence to the blood monitoring requirements and education relative to signs and symptoms of ITP has led to early detection and treatment of ITP with most cases responding to first-line medical therapy.

The potential risk associated with retreatment with LEMTRADA following the occurrence of ITP is unknown.

**Nephropathies:**
Nephropathies, including anti-glomerular basement membrane (anti-GBM) disease have been observed in 0.3% (5/1485) of patients in clinical trials in MS and occurred within 39 months following last administration of LEMTRADA. In clinical trials, there were 2 cases of anti-GBM disease. Both cases were serious, were identified early through clinical and laboratory monitoring, and had a positive outcome after treatment.

Clinical manifestations of nephropathy may include elevation in serum creatinine, hematuria, and/or proteinuria. While not observed in clinical trials, alveolar hemorrhage manifested as
hemoptysis may occur as a component of anti-GBM disease. Haemoptysis may also be indicative of ITP (see above), and an appropriate differential diagnosis should be undertaken. The patient should seek immediate medical help for any concerns. Anti-GBM disease may lead to renal failure requiring dialysis or transplantation and/or be fatal if not treated promptly.

Serum creatinine levels should be obtained prior to initiation of treatment and at monthly intervals thereafter until 48 months after the last infusion. Urinalysis with microscopy should be obtained prior to initiation of treatment and at monthly intervals thereafter until 48 months after the last infusion, and at any time afterwards testing should be performed immediately if nephropathy is suspected. The observation of clinically significant changes from baseline in serum creatinine, unexplained hematuria, and/or proteinuria, should prompt further evaluation for nephropathies, including referral to a specialist. Early detection and treatment of nephropathies may decrease the risk of poor outcomes.

The potential risk associated with retreatment with LEMTRADA following the occurrence of nephropathies is unknown.

**Thyroid Disorders:**
In controlled clinical trials, 11/1188 (0.9%) patients in the alemtuzumab group had a thyroid serious adverse event (SAE) versus 0/496 patients in the IFNb-1a group. In all follow-up studies, 23/1485 (1.5%) patients treated with alemtuzumab had a thyroid SAE, and 12/1485 (0.8%) patients required thyroidectomy. Serious events that occurred in more than one patient included Graves’ disease, hyperthyroidism, and hypothyroidism.

13 events of endocrine ophthalmopathy were reported in 11 (0.9%) patients in the alemtuzumab 12 mg/day group. All but one event were reported 2 years after alemtuzumab treatment initiation. Seven (7/11) had previously been diagnosed with Graves’ disease and 1 had been diagnosed with autoimmune thyroiditis. One serious adverse event of endocrine ophthalmopathy related to alemtuzumab was reported within 2 years of follow-up and required surgical decompression.

Thyroid function tests (TFTs), such as thyroid stimulating hormone (TSH) levels, should be obtained prior to initiation of treatment and every 3 months thereafter until 48 months after the last infusion. Testing should be performed immediately if thyroid dysfunction is suspected at any time during or after treatment with alemtuzumab.

Thyroid disease poses special risks in women who are pregnant (see WARNINGS and PRECAUTIONS, Special Populations, Pregnant Women). Without treatment of hypothyroidism during pregnancy, there is an increased risk for miscarriage and fetal effects such as mental retardation and dwarfism. In mothers with Graves’ disease, maternal thyroid stimulating hormone receptor antibodies can be transferred to a developing fetus and can cause transient neonatal Graves’ disease.

**Cytopenias:**
Suspected autoimmune cytopenias such as neutropenia, hemolytic anemia, and pancytopenia have been reported in patients in clinical trials in MS. Complete blood count (CBC) results
should be used to monitor for cytopenias. If a cytopenia is confirmed, appropriate medical intervention should be promptly initiated, including referral to a specialist.

**Immunization**

It is recommended that patients have completed local immunization requirements at least 6 weeks prior to treatment with LEMTRADA. The ability to generate an immune response to any vaccine following LEMTRADA treatment has not been studied.

**Live Vaccines**

The safety of immunization with live viral vaccines following a course of LEMTRADA treatment has not been formally studied in controlled clinical trials in MS and should not be administered to MS patients who have recently received a course of LEMTRADA.

**Varicella zoster virus antibody testing/vaccination:**

As for any immune modulating drug, before initiating a course of LEMTRADA treatment, patients without a history of chickenpox or without vaccination against varicella zoster virus (VZV) should be tested for antibodies to VZV. VZV vaccination of antibody-negative patients should be considered prior to treatment initiation with LEMTRADA. To allow for the full effect of the VZV vaccination to occur, postpone treatment with LEMTRADA for 6 weeks following vaccination.

**Infections**

Infections occurred in 71% of patients treated with LEMTRADA 12 mg as compared to 53% of patients treated with Rebif® (interferon beta-1a [IFNB-1a]) in controlled clinical trials in MS up to 2 years in duration. Infections that occurred more often in LEMTRADA-treated patients than IFNB-1a patients included nasopharyngitis, urinary tract infection, upper respiratory tract infection, sinusitis, oral herpes, influenza, and bronchitis. Serious infections occurred in 25 (2.7%) of patients treated with LEMTRADA as compared to 5 (1.0%) of patients treated with IFNB-1a in controlled clinical trials in MS. Serious infections in the LEMTRADA group that occurred in more than two patients included appendicitis, gastroenteritis, pneumonia, herpes zoster, and tooth infection. No serious infections occurred in more than 2 patients in the IFNB-1a group.

Serious varicella zoster virus infections, including primary varicella and varicella zoster re-activation, have occurred more often in patients treated with LEMTRADA 12 mg (0.3%) in clinical trials as compared to IFNB-1a (0%). Cervical human papilloma virus (HPV) infection, including cervical dysplasia, has also been reported in patients treated with LEMTRADA 12 mg (2%). It is recommended that HPV screening be completed annually for female patients.

Tuberculosis has been reported for patients treated with LEMTRADA and IFNB-1a in controlled clinical trials. Active and latent tuberculosis have been reported in 0.3% of the patients treated with LEMTRADA, most often in endemic regions. Before initiating therapy with LEMTRADA, all patients must be evaluated for both active and inactive (“latent”) tuberculosis infection.
Superficial fungal infections, especially oral and vaginal candidiasis, occurred more commonly in LEMTRADA-treated patients (12%) than in patients treated with IFNB-1a (3%) in clinical trials in MS.

Physicians should consider delaying initiation of LEMTRADA administration in patients with active infection until the infection is fully controlled.

Prophylaxis with an oral anti-herpes agent should be initiated starting on the first day of LEMTRADA treatment and continuing for a minimum of 1 month following each course of treatment.

LEMTRADA has not been administered for the treatment of MS concomitantly with antineoplastic or immunosuppressive therapies. Concomitant use of LEMTRADA with any of these therapies could increase the risk of immunosuppression.

No data are available on the association of LEMTRADA with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) reactivation as patients with evidence of active or chronic infections were excluded from clinical trials. Screening patients at high risk of HBV and/or HCV infection before initiation of LEMTRADA should be considered and caution should be exercised in prescribing LEMTRADA to patients identified as carriers of HBV and/or HCV as these patients may be at risk of irreversible liver damage relative to a potential virus reactivation as a consequence of their pre-existing status.

**Special Populations**

**Pregnant Women:** There are no adequate and well-controlled studies of LEMTRADA in pregnant women.

Human IgG is known to cross the placental barrier; alemtuzumab may cross the placental barrier as well and thus potentially pose a risk to the fetus.

In all clinical trials with Lemtrada, a total of 72 pregnancies in female patients treated with alemtuzumab have been reported. Of these, 10 were reported between treatment Cycle 1 and Cycle 2. Two (2/10) had spontaneous abortions (< 20 weeks), and there were 4 elective abortions.

The remaining 62 pregnancies occurred after Cycle 2. Of 62 patients, 3 had preterm pregnancies (> 32 weeks), 14 had spontaneous abortion, 5 had elective abortions, with 1 still birth, and 11 pregnancies with unknown outcomes.

LEMTRADA is not recommended in pregnant women.

Women of child bearing potential should use effective contraceptive measures when receiving a course of treatment with LEMTRADA and for 4 months following that course of treatment.

Thyroid disease (see WARNINGS and PRECAUTIONS, Immune, Autoimmunity, Thyroid Disorders) poses special risks in women who are pregnant.
Nursing Women: It is not known whether LEMTRADA is excreted in human milk. Because many drugs are excreted in human milk, breast feeding should be discontinued during each course of treatment with LEMTRADA and for 4 months following the last infusion of each treatment course.

Pediatrics (< 18 years of age): The safety and efficacy of LEMTRADA in pediatric MS patients below the age of 18 years of age have not been established.

Geriatrics (≥ 65 years of age): Clinical studies of LEMTRADA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.

Monitoring and Laboratory Tests
Laboratory tests should be conducted at periodic intervals continuously during treatment with LEMTRADA plus for at least 48 months following the last treatment course of LEMTRADA in order to monitor for early signs of autoimmune disease:

- CBC with differential (prior to treatment initiation and at monthly intervals thereafter)
- Serum creatinine levels (prior to treatment initiation and at monthly intervals thereafter)
- Urinalysis with urine cell counts (prior to treatment initiation and at monthly intervals thereafter)
- A test of thyroid function, such as TSH level (prior to treatment initiation and every 3 months thereafter)

ADVERSE REACTIONS

Adverse Drug Reaction Overview

The most common adverse reactions with LEMTRADA 12 mg (in approximately ≥10% of patients and greater than IFNB-1a) were headache, rash, pyrexia, nasopharyngitis, nausea, fatigue, urinary tract infection, urticaria, insomnia, pruritus, upper respiratory tract infection, pain in extremity, arthralgia, back pain, paraesthesia, diarrhea, oropharyngeal pain, sinusitis, vomiting, dizziness, contusion, chills and flushing; most of which were reported as infusion associated reactions. The most frequently reported serious adverse reactions with LEMTRADA 12 mg (in ≥0.4% of patients and greater than IFNB-1a) were pneumonia, autoimmune thrombocytopenia, gastroenteritis, appendicitis, and urticaria. The most frequent adverse events leading to permanent discontinuation of LEMTRADA treatment were non-cardiac chest pain (0.3%) and infusion related reaction, hypothyroidism, dyspnea, and MS relapse (0.2% each).

Most patients in the LEMTRADA 12 mg group experienced IARs, and the majority of IARs were mild to moderate in severity. Slowing or interrupting a protein therapeutic infusion is a common way to control for IARs (Dillman, 2003, Support Cancer Ther). The most common IARs leading to dose adjustment (e.g. temporary interruption, slowed rate of infusion) were urticaria, chills, headache, rash, pyrexia, nausea, and hypotension (see WARNINGS AND PRECAUTIONS). Other significant adverse events with LEMTRADA 12 mg included
autoimmune events (immune thrombocytopenic purpura, nephropathies, and thyroid disorders) and infections (see WARNINGS AND PRECAUTIONS).

**Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

A total of 1188 patients with relapsing remitting MS (RRMS) treated with LEMTRADA (12 or 24 mg) constituted the safety population in the pooled analysis of controlled clinical studies resulting in 2363 patient-years of safety follow-up and a median follow-up of 24 months in 3 active controlled trials (see CLINICAL TRIALS). CAMMS32400507 and CAMMS323 were 2-year active-controlled trials and CAMMS223 was a 3-year active-controlled study with an extension up to 2 years. All 3 studies were in RRMS patients treated with LEMTRADA 12 mg or 24 mg for 5 consecutive days at study entry and for 3 consecutive days at Study Month 12, or subcutaneous (SC) IFNB-1a 44 µg 3 times per week.

Table 1 lists adverse reactions occurring in ≥1% of LEMTRADA-treated patients (12 mg/day) regardless of causality in a 2-year analysis of CAMMS32400507, CAMMS323 and CAMMS223.

Table 1: Adverse Events\(^1\) in Active Controlled Studies (CAMMS32400507, CAMMS323 and CAMMS223) Reported for LEMTRADA 12 mg Treated Patients (occurring in ≥1% of LEMTRADA-treated patients)

<table>
<thead>
<tr>
<th>System Organ Class Preferred Term</th>
<th>LEMTRADA 12 mg (N=919) %</th>
<th>REBIF® 44 µg (N=496) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>48.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Urticaria</td>
<td>17.0</td>
<td>1.8</td>
</tr>
<tr>
<td>Pruritus</td>
<td>16.5</td>
<td>2.2</td>
</tr>
<tr>
<td>Rash generalised</td>
<td>7.7</td>
<td>0.8</td>
</tr>
<tr>
<td>Erythema</td>
<td>5.7</td>
<td>2.8</td>
</tr>
<tr>
<td>Alopecia</td>
<td>3.2</td>
<td>1.8</td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>3.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Rash erythematous</td>
<td>2.9</td>
<td>0.4</td>
</tr>
<tr>
<td>Acne</td>
<td>2.8</td>
<td>1.4</td>
</tr>
<tr>
<td>Dermatitis allergic</td>
<td>2.7</td>
<td>1.0</td>
</tr>
<tr>
<td>Rash pruritic</td>
<td>2.5</td>
<td>0</td>
</tr>
</tbody>
</table>
Table 1: Adverse Events\(^1\) in Active Controlled Studies (CAMMS32400507, CAMMS323 and CAMMS223) Reported for LEMTRADA 12 mg Treated Patients (occurring in \(\geq 1\%\) of LEMTRADA-treated patients)

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Preferred Term</th>
<th>LEMTRADA 12 mg (N=919)</th>
<th>REBIF(^{\circledast}) 44 µg (N=496)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Pruritus generalised</td>
<td>2.4</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Increased tendency to bruise</td>
<td>2.1</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Hypoesthesia facial</td>
<td>1.8</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Rash papular</td>
<td>1.5</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Dry skin</td>
<td>1.3</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Petechiae</td>
<td>1.3</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Blister</td>
<td>1.1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>52.0</td>
<td>22.4</td>
<td></td>
</tr>
<tr>
<td>Paraesthesia</td>
<td>12.3</td>
<td>10.1</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>9.8</td>
<td>6.0</td>
<td></td>
</tr>
<tr>
<td>Balance disorder</td>
<td>2.8</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>2.3</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>23.5</td>
<td>16.5</td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>17.6</td>
<td>8.1</td>
<td></td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>15.3</td>
<td>11.5</td>
<td></td>
</tr>
<tr>
<td>Sinusitis</td>
<td>10.9</td>
<td>6.9</td>
<td></td>
</tr>
<tr>
<td>Oral herpes</td>
<td>8.6</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>8.4</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>Bronchitis</td>
<td>7.0</td>
<td>3.2</td>
<td></td>
</tr>
<tr>
<td>Rhinitis</td>
<td>4.4</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>4.1</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>3.9</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>3.9</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>Vulvovaginal candidiasis</td>
<td>3.3</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Ear infection</td>
<td>2.8</td>
<td>1.8</td>
<td></td>
</tr>
<tr>
<td>Oral candidiasis</td>
<td>2.5</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Cystitis</td>
<td>2.4</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Herpes simplex</td>
<td>1.8</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Vulvovaginal mycotic infection</td>
<td>1.5</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Genital herpes</td>
<td>1.3</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyrexia</td>
<td>29.9</td>
<td>9.3</td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>20.7</td>
<td>14.7</td>
<td></td>
</tr>
</tbody>
</table>
Table 1: Adverse Events\(^1\) in Active Controlled Studies (CAMMS32400507, CAMMS323 and CAMMS223) Reported for LEMTRADA 12 mg Treated Patients (occurring in ≥ 1% of LEMTRADA-treated patients)

<table>
<thead>
<tr>
<th>System Organ Class Preferred Term</th>
<th>LEMTRADA 12 mg (N=919)</th>
<th>REBIF(^\circledast) 44 µg (N=496)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chills</td>
<td>9.7</td>
<td>3.6</td>
</tr>
<tr>
<td>Chest discomfort</td>
<td>7.6</td>
<td>1.8</td>
</tr>
<tr>
<td>Pain</td>
<td>7.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Asthenia</td>
<td>5.7</td>
<td>3.4</td>
</tr>
<tr>
<td>Oedema peripheral</td>
<td>5.1</td>
<td>2.4</td>
</tr>
<tr>
<td>Hyperthermia</td>
<td>2.8</td>
<td>0.6</td>
</tr>
<tr>
<td>Chest pain</td>
<td>1.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Catheter site pain</td>
<td>1.4</td>
<td>0</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>21.5</td>
<td>9.9</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11.6</td>
<td>5.8</td>
</tr>
<tr>
<td>Vomiting</td>
<td>10.2</td>
<td>4.0</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>8.6</td>
<td>4.8</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>5.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Abdominal pain upper</td>
<td>4.4</td>
<td>1.8</td>
</tr>
<tr>
<td>Abdominal discomfort</td>
<td>2.3</td>
<td>1.2</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>1.6</td>
<td>0.4</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>1.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Mouth ulceration</td>
<td>1.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>13.1</td>
<td>9.3</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>12.5</td>
<td>8.7</td>
</tr>
<tr>
<td>Back pain</td>
<td>12.4</td>
<td>7.5</td>
</tr>
<tr>
<td>Myalgia</td>
<td>6.7</td>
<td>5.6</td>
</tr>
<tr>
<td>Neck pain</td>
<td>4.9</td>
<td>2.4</td>
</tr>
<tr>
<td>Muscle tightness</td>
<td>2.3</td>
<td>0.6</td>
</tr>
<tr>
<td>Musculoskeletal chest pain</td>
<td>1.6</td>
<td>0.4</td>
</tr>
<tr>
<td>Joint swelling</td>
<td>1.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oropharyngeal pain</td>
<td>11.0</td>
<td>4.6</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>9.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Cough</td>
<td>9.0</td>
<td>3.8</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>4.6</td>
<td>1.8</td>
</tr>
<tr>
<td>Sinus congestion</td>
<td>2.7</td>
<td>1.0</td>
</tr>
</tbody>
</table>
Table 1: Adverse Events\(^1\) in Active Controlled Studies (CAMMS32400507, CAMMS323 and CAMMS223) Reported for LEMTRADA 12 mg Treated Patients (occurring in ≥ 1% of LEMTRADA-treated patients)

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Preferred Term</th>
<th>LEMTRADA 12 mg (N=919) %</th>
<th>REBIF(^\circledast) 44 µg (N=496) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal congestion</td>
<td>2.3</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Wheezing</td>
<td>1.6</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Bronchospasm</td>
<td>1.3</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>16.8</td>
<td>14.9</td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4 lymphocytes decreased</td>
<td>5.3</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>CD8 lymphocytes decreased</td>
<td>5.3</td>
<td>1.8</td>
<td></td>
</tr>
<tr>
<td>Blood urine present</td>
<td>4.2</td>
<td>1.8</td>
<td></td>
</tr>
<tr>
<td>T-lymphocyte count decreased</td>
<td>4.2</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>Lymphocyte count decreased</td>
<td>3.9</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>B-lymphocyte count decreased</td>
<td>3.7</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Bacterial test positive</td>
<td>2.7</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>Lymphocyte percentage decreased</td>
<td>2.6</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Body temperature increased</td>
<td>2.5</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Blood thyroid stimulating hormone decreased</td>
<td>2.3</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Protein urine present</td>
<td>2.2</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Lymphocyte percentage increased</td>
<td>2.0</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Urine analysis abnormal</td>
<td>1.3</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contusion</td>
<td>9.8</td>
<td>5.8</td>
<td></td>
</tr>
<tr>
<td>Joint sprain</td>
<td>2.4</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flushing</td>
<td>9.5</td>
<td>4.0</td>
<td></td>
</tr>
<tr>
<td>Hypotension</td>
<td>2.7</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Haematoma</td>
<td>1.2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Peripheral coldness</td>
<td>1.1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision blurred</td>
<td>4.7</td>
<td>3.4</td>
<td></td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>2.3</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematuria</td>
<td>3.0</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Proteinuria</td>
<td>2.1</td>
<td>0.6</td>
<td></td>
</tr>
</tbody>
</table>
Table 1: Adverse Events\(^1\) in Active Controlled Studies (CAMMS32400507, CAMMS323 and CAMMS223) Reported for LEMTRADA 12 mg Treated Patients (occurring in ≥ 1% of LEMTRADA-treated patients)

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Preferred Term</th>
<th>LEMTRADA 12 mg (N=919)</th>
<th>REBIF(^\circ) 44 µg (N=496)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tachycardia</td>
<td>8.1</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>Palpitations</td>
<td>3.8</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Bradycardia</td>
<td>2.9</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Menorrhagia</td>
<td>3.9</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Menstruation irregular</td>
<td>2.3</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Vaginal hemorrhage</td>
<td>1.4</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>5.5</td>
<td>2.6</td>
<td></td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>4.6</td>
<td>1.6</td>
<td></td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>3.5</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Basedow's disease</td>
<td>2.4</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Autoimmune thyroiditis</td>
<td>1.7</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Goitre</td>
<td>1.4</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vertigo</td>
<td>4.4</td>
<td>2.8</td>
<td></td>
</tr>
<tr>
<td>Ear pain</td>
<td>2.5</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytokine release syndrome</td>
<td>1.6</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) Adverse events in at least 1% more patients in LEMTRADA compared to REBIF.

**Immunogenicity:**
As with all therapeutic proteins, there is potential for immunogenicity. Data reflect the percentage of patients whose test results were considered positive for antibodies to alemtuzumab using an enzyme-linked immunosorbent assay (ELISA) and confirmed by a competitive binding assay. Positive samples were further evaluated for evidence of *in vitro* inhibition using a flow cytometry assay. Patients in controlled clinical trials in MS had serum samples collected 1, 3, and 12 months after each treatment course for determination of anti-alemtuzumab antibodies. Approximately 85% of patients receiving LEMTRADA tested positive for anti-alemtuzumab antibodies during the study with 92% of these patients testing positive also for antibodies that inhibited LEMTRADA binding *in vitro*. Patients who developed anti-alemtuzumab antibodies did so by 15 months from initial exposure. There was no apparent association of the presence of anti-alemtuzumab or inhibitory anti-alemtuzumab antibodies with a reduction in efficacy, change...
in pharmacodynamics, or the occurrence of adverse reactions, including infusion associated reactions.

The incidence of antibodies is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including inhibitory antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to LEMTRADA with the incidence of antibodies to other products may be misleading.

**Less Common Clinical Trial Adverse Drug Reactions (<1%)**

The following lists adverse reactions occurring in <1% of LEMTRADA-treated patients (12 mg/day) occurring in 2 or more patients considered related to study drug in a 2-year analysis of CAMMS32400507, CAMMS323 and CAMMS223.

**Blood and lymphatic system disorders**
Thrombocytopenia, autoimmune thrombocytopenia, monocytopenia, anemia, microcytic anemia, eosinophilia, idiopathic thrombocytopenic purpura, iron deficiency anemia

**Cardiac disorders**
Sinus tachycardia, sinus bradycardia, angina pectoris, atrial fibrillation

**Ear and labyrinth disorders**
Ear pain, vertigo positional, ear pruritus, tinnitus

**Endocrine disorders**
Thyroiditis, thyroiditis subacute

**Eye disorders**
Conjunctivitis, eye pain, visual impairment, dry eye, eyelid oedema, periorbital oedema, photophobia

**Gastrointestinal disorders**
Mouth ulceration, abdominal distension, constipation, gastrooesophageal reflux disease, gingival bleeding, dysphagia, aphthous stomatitis, gingivitis, dry mouth, gastritis, haematochezia, tongue discoloration, toothache, flatulence, gastrointestinal disorder, gingival pain, glossodynia, oesophagitis

**General disorders and administration site conditions**
Catheter site pain, infusion site pain, non-cardiac chest pain, chest pain, feeling cold, infusion related reaction, oedema, catheter site erythema, catheter site rash, face oedema, facial pain, feeling of body temperature change, gait disturbance, infusion site extravasation, infusion site reaction, irritability, mucosal inflammation

**Immune system disorders**
Seasonal allergy
Infections and infestations
Ear infection, gastroenteritis, vulvovaginal mycotic infection, genital herpes, viral infection, viral upper respiratory tract infection, candidiasis, cystitis, lower respiratory tract infection, laryngitis, onychomycosis, otitis media, pharyngitis streptococcal, respiratory tract infection, respiratory tract infection viral, tooth infection, pneumonia, tooth abscess, cellulitis, fungal infection, fungal skin infection, tinea versicolour, tonsillitis, vaginitis bacterial, asymptomatic bacteriuria, bacteriuria, bronchitis viral, cervicitis, furuncle, gastroenteritis viral, H1N1 influenza, labyrinthitis, oesophageal candidiasis, pyelonephritis, skin infection, tinea infection, tinea pedis, tracheobronchitis, urethritis, vaginal infection, varicella

Injury, poisoning and procedural complications
Incorrect dose administered

Investigations
Anti-thyroid antibody positive, neutrophil count decreased, white blood cells urine positive, aspartate aminotransferase increased, blood pressure increased, haemoglobin decreased, heart rate increased, thyroxine free decreased, bacterial test positive, haematocrit decreased, red blood cells urine positive, weight decreased, alanine aminotransferase increased, eosinophil count decreased, liver function test abnormal, tri-iodothyronine free increased, blood alkaline phosphatase increased, glucose urine present, tri-iodothyronine free decreased, weight increased, white blood cell count increased, blood bilirubin increased, CD4/CD8 ratio decreased, crystal urine present, human papilloma virus test positive, monocyte count increased, natural killer cell count increased, respiratory rate increased, thyroxine free increased, urinary casts

Metabolism and nutrition disorders
Decreased appetite, dehydration

Musculoskeletal and connective tissue disorders
Musculoskeletal pain, musculoskeletal chest pain, muscle tightness, sensation of heaviness, musculoskeletal stiffness, bone pain, joint stiffness, joint swelling, limb discomfort

Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin papilloma

Nervous system disorders
Burning sensation, migraine, hyperaesthesia, sensory disturbance, multiple sclerosis, somnolence, dysaesthesia, syncope, allodynia, ataxia, balance disorder, coordination abnormal, disturbance in attention, hemiparesis, memory impairment, muscle spasticity, neuropathy peripheral, post herpetic neuralgia, presyncope, psychomotor hyperactivity, restless legs syndrome, tension headache

Psychiatric disorders
Depression, restlessness, agitation, dyssomnia
Renal and urinary disorders
Dysuria, leukocyturia, micturition urgency, pollakiuria, urinary incontinence, urine abnormality

Reproductive system and breast disorders
Cervical dysplasia, amenorrhea, vaginal hemorrhage, dysmenorrhea, metrorrhagia, menstrual disorder, ovarian cyst

Respiratory, thoracic and mediastinal disorders
Sinus congestion, hiccups, throat irritation, throat tightness, dyspnea exertional, pharyngeal erythema, asthma, dysphonia, pleurisy, rhinorrhea, choking sensation, haemoptysis, oropharyngeal blistering, painful respiration, productive cough, upper respiratory tract congestion, upper-airway cough syndrome

Skin and subcutaneous tissue disorders
Petechiae, rash maculo-papular, blister, ecchymosis, night sweats, cold sweat, eczema, hypoaesthesia facial, skin lesion, dermatitis, rash macular, skin hyperpigmentation, swelling face, angioedema, dry skin, papule, pityriasis rosea, prurigo, skin exfoliation, skin hypopigmentation, skin irritation

Surgical and medical procedures
Thyroidectomy

Vascular disorders
Hyperaemia, pallor, haematoma, peripheral coldness, blood pressure fluctuation

Abnormal Hematologic and Clinical Chemistry Findings
A rapid depletion of circulating T and B lymphocytes is believed to be linked to the mechanism of action of LEMTRADA and results in nearly all patients in MS clinical trials experiencing lymphopenia following treatment. The lowest observed values occurred by 1 month after each course of treatment. The mean lymphocyte count at 1 month after treatment was 0.25 x 10^9L (range 0.02-2.30 x 10^9L) and 0.32 (0.02-1.81 x 10^9L) for treatment courses 1 and 2, respectively. Total lymphocyte counts increased to reach the lower limit of normal in approximately 40% of patients by 6 months after each treatment course and approximately 80% of patients by 12 months after each course.

Post-Market Adverse Drug Reactions:

The following adverse reactions were identified during post-approval use of alemtuzumab for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) (marketed as MabCampath®), as well as for the treatment of other disorders, generally at higher and more frequent doses (e.g., 30 mg) than that recommended in the treatment of MS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Autoimmune Disease
Autoimmune events reported in alemtuzumab-treated patients include neutropenia, hemolytic anemia (including a fatal case), acquired hemophilia, anti-GBM disease, and thyroid disease. Serious and sometimes fatal autoimmune phenomena including autoimmune hemolytic anemia, autoimmune thrombocytopenia, aplastic anemia, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyradiculoneuropathy have been reported in alemtuzumab-treated non-MS patients. A positive Coombs test has been reported in an alemtuzumab-treated oncology patient. A fatal event of transfusion associated graft versus host disease has been reported in an alemtuzumab-treated oncology patient.

Infusion Associated Reactions
Serious and sometimes fatal IARs including bronchospasm, hypoxia, syncope, pulmonary infiltrates, acute respiratory distress syndrome, respiratory arrest, myocardial infarction, arrhythmias, acute cardiac insufficiency, and cardiac arrest have been observed in non-MS patients treated with alemtuzumab at higher and more frequent doses than used in MS. Severe anaphylaxis and other hypersensitivity reactions, including anaphylactic shock and angioedema have also been reported.

Infections and Infestations
Serious and sometimes fatal viral, bacterial, protozoan, and fungal infections, including those due to reactivation of latent infections, have been reported in non-MS patients treated with alemtuzumab at higher and more frequent doses than used in MS. Progressive multifocal leukoencephalopathy (PML) has been reported in patients with B-CLL with or without treatment with alemtuzumab. The frequency of PML in B-CLL patients treated with alemtuzumab is no greater than the background frequency.

Blood and Lymphatic System Disorders
Severe bleeding reactions have been reported in non-MS patients.

Cardiac Disorders
Congestive heart failure, cardiomyopathy, and decreased ejection fraction have been reported in alemtuzumab-treated non-MS patients previously treated with potentially cardiotoxic agents.

Epstein-Barr Virus-associated Lymphoproliferative Disorders
The majority of Epstein Barr Virus-associated lymphoproliferative disorders been observed in postmarketing experience.

For more information, please consult the MabCampath Product Monograph.

DRUG INTERACTIONS

Drug-Drug Interactions
No formal drug interaction studies have been conducted with LEMTRADA using the recommended dose in patients with MS. In a controlled clinical trial in MS (Study 1), patients recently treated with beta interferon and glatiramer acetate were required to discontinue treatment 28-days before initiating treatment with LEMTRADA.
**Drug-Food Interactions**
LEMTRADA is administered parenterally, therefore interactions with food and drink are unlikely.

**Drug-Laboratory Interactions**
It is not known whether LEMTRADA interferes with any routine clinical laboratory tests.

**DOSAGE AND ADMINISTRATION**

LEMTRADA treatment should be initiated and supervised by a neurologist experienced in the treatment of patients with MS. Specialists and equipment required for the timely diagnosis and treatment of the most frequent adverse reactions (especially autoimmune conditions including infusion reactions and infections) should be available.

Resources for the treatment of hypersensitivity and anaphylactic reactions should be immediately available.

Patients treated with LEMTRADA must be given the Patient Alert Card and Patient Guide and be informed about the risks of LEMTRADA (see also package leaflet).

Specific pre-medication should be provided prior LEMTRADA administration (see Recommended Concomitant Medication).

**Dosing Considerations**
LEMTRADA should be administered under the supervision of a physician experienced in the use of immunomodulating therapies.

**Recommended Dose and Dosage Adjustment**
The recommended dose of LEMTRADA is 12 mg/day administered by intravenous (IV) infusion for 2 treatment courses:

- Initial Treatment Course: 12 mg/day for 5 consecutive days (60 mg total dose)
- Second Treatment Course: 12 mg/day for 3 consecutive days (36 mg total dose) administered 12 months after the initial treatment course.

LEMTRADA should be administered as an IV infusion over a period of approximately 4 hours. Do not administer as IV push or bolus.

**Recommended Concomitant Medications:**
Patients should be premedicated with corticosteroids immediately prior to LEMTRADA administration for the first 3 days of any treatment course (see WARNINGS and PRECAUTIONS, General, Infusion Associated Reactions). In clinical trials, patients were pretreated with 1,000 mg methylprednisolone for the first 3 days of each LEMTRADA treatment.
course. Pretreatment with antihistamines and/or antipyretics prior to LEMTRADA administration may also be considered.

Oral prophylaxis for herpes infection should be administered to all patients starting on the first day of each treatment course and continuing for a minimum of 1 month following treatment with LEMTRADA (see WARNINGS and PRECAUTIONS, Sensitivity/Resistance, Infections). In clinical trials, patients were administered acyclovir 200 mg BID or equivalent.

**Missed Dose**
Missed doses should not be given on the same day as a scheduled dose.

**Administration**
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if particulate matter is present or the solution is discolored. Do not freeze or shake vials prior to use. Protect from light.

For IV administration, withdraw 1.2 mL of LEMTRADA from the vial into a syringe using aseptic technique. Inject into 100 mL sterile 0.9% Sodium Chloride USP or 5% Dextrose in Water USP. Gently invert the bag to mix the solution. Care should be taken to ensure the sterility of the prepared solution, particularly as it contains no antimicrobial preservatives. Each vial is intended for single use only.

LEMTRADA diluted product may be stored at room temperature (15° to 25°C) or refrigerated conditions (2° to 8°C). The LEMTRADA diluted product should be used within 8 hours after dilution. Protect from light. Partially used, unused, or damaged drug vials should be disposed according to institutional policies.

There are no known incompatibilities between LEMTRADA and polyvinyl chloride (PVC) infusion bags, PVC or polyethylene-lined PVC administration sets, or low protein binding filters. In the absence of compatibility studies, LEMTRADA should not be mixed with other medicinal products. Do not add or simultaneously infuse other drug substances through the same intravenous line.

**OVERDOSAGE**

| For management of a suspected drug overdose, please contact your Regional Poison Control Centre |

Two MS patients accidentally received up to 60 mg LEMTRADA (i.e., total dose for initial treatment) in a single infusion and experienced serious reactions (headache, rash, and either hypotension or sinus tachycardia). Doses of LEMTRADA greater than those tested in clinical studies may increase the intensity and/or duration of infusion-associated adverse reactions or its immune effects.

There is no known antidote for LEMTRADA overdosage. Treatment consists of drug
discontinuation and supportive therapy.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**
Alemtuzumab binds to CD52, a cell surface antigen present at high levels on T and B lymphocytes, and at lower levels on natural killer cells, monocytes, and macrophages. There is little or no CD52 detected on neutrophils, plasma cells, or bone marrow stem cells. Alemtuzumab acts through antibody-dependent cellular cytolysis and complement-mediated lysis following cell surface binding to B and T lymphocytes.

The mechanism by which alemtuzumab exerts its therapeutic effects in MS is not fully elucidated, but may involve immunomodulation through the depletion and repopulation of lymphocytes. Research suggests that potential immunomodulatory effects may include alterations in the number, proportions, and properties of some lymphocyte subsets post treatment.

**Pharmacodynamics**
LEMTTRADA depletes circulating T and B lymphocytes after each treatment course with the lowest observed values occurring 1 month after a course of treatment (the earliest post-treatment time point in Study 1 and 2). Lymphocytes repopulate over time with B cell recovery usually completed within 6 months. T lymphocyte counts rise more slowly towards normal, but generally do not return to baseline by 12 months post treatment. Approximately 40% of patients had total lymphocyte counts reaching the lower limit of normal (LLN) by 6 months after each treatment course and approximately 80% of patients had total lymphocyte counts reaching the LLN by 12 months after each course. Neutrophils, monocytes, eosinophils, basophils, and natural killer cells are only transiently affected by LEMTRADA.

**Pharmacokinetics**
The pharmacokinetics of alemtuzumab were evaluated in a total of 216 patients with RRMS who received IV infusions of either 12 mg/day or 24 mg/day for 5 consecutive days, followed by 3 consecutive days 12 months following the initial treatment course. Serum concentrations increased with each consecutive dose within a treatment course, with the highest observed concentrations occurring following the last infusion of a treatment course. Administration of 12 mg/day resulted in a mean C\text{max} of 3014 ng/mL on Day 5 of the initial treatment course, and 2276 ng/mL on Day 3 of the second treatment course. The alpha half-life approximated 2 days and was comparable between cycles leading to low or undetectable serum concentrations within approximately 30 days following each treatment cycle.

The population pharmacokinetics of alemtuzumab were best described by a linear, 2 compartment model. The influence of lymphocyte count on systemic clearance was significant, which is consistent with the fact that alemtuzumab targets CD52+ lymphocytes; however, the decrease from cycle 1 to cycle 2 was less than 20%. The central volume of distribution was proportional to body weight, and approximated extracellular fluid volume (14.1 L), suggesting that alemtuzumab is largely confined to the blood and interstitial space.
Alemtuzumab is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by widely distributed proteolytic enzymes.

**Special Populations and Conditions**

**Pediatrics:** No specific studies have been conducted to investigate the pharmacokinetics of LEMTRADA in pediatric patients. However, a population pharmacokinetic analysis showed no effect of age (age range: 20-53 years old) on LEMTRADA pharmacokinetics.

**Geriatrics:** No specific studies have been conducted to investigate the pharmacokinetics of LEMTRADA in geriatric patients. However, a population pharmacokinetic analysis showed no effect of age (age range: 20-53 years old) on LEMTRADA pharmacokinetics.

**Gender:** A population pharmacokinetic analysis showed no effect of gender on LEMTRADA pharmacokinetics.

**Race:** A population pharmacokinetic analysis showed no effect of race on LEMTRADA pharmacokinetics.

**Hepatic Insufficiency:** The effects of hepatic impairment on the pharmacokinetics of LEMTRADA have not been studied.

**Renal Insufficiency:** The effects of renal impairment on the pharmacokinetics of LEMTRADA have not been studied.

**STORAGE AND STABILITY**

**Vials**

LEMTTRA vials should be stored at 2° to 8°C. Do not freeze or shake. Protect from light.

**Infusion solution**

LEMTTRA diluted product may be stored at room temperature (15° to 25°C) or refrigerated conditions (2° to 8°C). The LEMTRADA diluted product should be used within 8 hours after dilution. Protect from light. Partially used, unused, or damaged drug vials should be disposed according to institutional policies.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

LEMTTRA is provided as a sterile, clear, colorless to slightly yellow, preservative-free, concentrate solution that must be diluted prior to IV infusion. It is filled in a clear, single use, 2 mL glass vial, with a latex-free stopper.

Each 2 mL LEMTRADA vial is filled to deliver 1.2 mL of 10 mg/mL solution (12 mg LEMTRADA). Each carton contains a single LEMTRADA vial.
**Non-medicinal ingredients:** Each 1.0 mL of concentrate solution contains the following non-medicinal ingredients: 8.0 mg sodium chloride, 1.15 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg potassium dihydrogen phosphate, 0.1 mg polysorbate 80, 0.0187 mg disodium edetate dihydrate, and water for injection.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Common name: alemutuzumab

Structural formula:

![Structural formula diagram]

Physicochemical properties: Alemtuzumab is a recombinant DNA-derived humanized monoclonal antibody that is directed against the 21-28 kD cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa antibody with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a nutrient medium.

The alemtuzumab antibody has an approximate molecular weight of 150 kilodaltons (kD). Alemtuzumab is a Y-shaped molecule consisting of two 24 kDa light polypeptide chains (L-C) and two 49 kDa heavy polypeptide chains (H-C) linked together by two interdisulfide (L-C)-(H-C) bridges and two interdisulfide (H-C)-(H-C) bridges. Each molecule also contains a total of 12 intrachain disulfide bridges and an asparagine residue in each heavy chain that is amenable to glycosylation.
CLINICAL TRIALS

Study demographics and trial design
The safety of LEMTRADA (alemtuzumab) is based on the assessment of data from 3 clinical trials in patients with Relapsing Remitting Multiple Sclerosis (RRMS).

The efficacy assessment of alemtuzumab 12 mg/day is based on Study CAMMS32400507. The purpose of this Phase 3, randomized, rater-blinded study was to evaluate the safety and efficacy of alemtuzumab compared with subcutaneous (SC) interferon beta-1a (IFNB-1a, Rebif®), in patients with active relapsing-remitting multiple sclerosis (RRMS) who had experienced at least 1 relapse during prior treatment with interferon beta or glatiramer acetate after having received that therapy for ≥ 6 months.

CAMMS32400507 enrolled patients with MS who had been treated with interferon beta or glatiramer acetate and experienced at least 2 clinical episodes during the prior 2 years. Neurological examinations were performed every 12 weeks and at times of suspected relapse. MRI evaluations were performed annually. Patients were followed for 2 years. Patients were randomized to receive LEMTRADA 12 mg/day IV infusion administered once per day for 5 days at Month 0 and for 3 days at Month 12 (12 mg group) or IFNB-1a 44 µg SC injection administered 3 times per week. This study also included an exploratory dose arm for LEMTRADA 24 mg/day administered once per day for 5 days at Month 0 and for 3 days at Month 12 (24 mg group). The primary outcome measures were the annualized relapse rate (ARR) over 2 years and the time to onset of sustained accumulation of disability (SAD), defined as an increase of at least 1 point on the expanded disability status scale (EDSS) from baseline EDSS ≥ 1.0 (1.5 point increase for patients with baseline EDSS of 0) that was sustained for 6 months.

The mean duration of prior MS disease modifying treatment was 36 months; 29% (182/637) of patients had tried 2 or more treatments. 83% (526/637) had prior exposure to an interferon-beta, and 34% (218/637) had prior exposure to glatiramer acetate.

The trial design and patient demographics for these studies is summarized in Table 2.
### Table 2: Summary of Trial Design and Patient Demographics for Clinical Trials of LEMTRADA in RRMS

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n=number)</th>
<th>Mean age (Range)</th>
<th>Gender (M/F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>Phase 3, randomized, rater-blinded, active-comparator, multi-center</td>
<td><em>LEMTRADA</em> Cycle 1, month 0: 12 mg/day OR 24 mg/day for 5 days</td>
<td>LEMTRADA 12 mg: 426</td>
<td>LEMTRADA 12 mg: 34.8 years (18-55 years)</td>
<td>LEMTRADA 12 mg: 34.0%/66.0%</td>
</tr>
<tr>
<td>(CAMMS32400507)</td>
<td>(Patients with inadequate response to prior therapy)</td>
<td>Cycle 2, month 12: 12 mg/day OR 24 mg/day for 3 days</td>
<td>LEMTRADA 24 mg: 170</td>
<td>LEMTRADA 24 mg: 35.1 years (20-54 years)</td>
<td>LEMTRADA 24 mg: 29.4%/70.6%</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>IFNB-1a</em> 44 mcg SC injections 3 times per week for 24 months</td>
<td>IFNB-1a: 202</td>
<td>IFNB-1a: 35.8 years (18-54 years)</td>
<td>IFNB-1a: 35.1%/64.9%</td>
</tr>
<tr>
<td>Study 2</td>
<td>Phase 3, randomized, rater-blinded, active-comparator, multi-center</td>
<td><em>LEMTRADA</em> Cycle 1, month 0: 12 mg/day for 5 days</td>
<td>LEMTRADA 12 mg: 376</td>
<td>LEMTRADA 12 mg: 33.0 years (18-51 years)</td>
<td>LEMTRADA 12 mg: 35.4%/64.6%</td>
</tr>
<tr>
<td>(CAMMS323)</td>
<td>(Treatment-naïve patients)</td>
<td>Cycle 2, month 12: 12 mg/day for 3 days</td>
<td>IFNB-1a: 187</td>
<td>IFNB-1a: 33.2 years (18-53 years)</td>
<td>IFNB-1a: 34.8%/65.2%</td>
</tr>
</tbody>
</table>
Table 2: Summary of Trial Design and Patient Demographics for Clinical Trials of LEMTRADA in RRMS

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n=number)</th>
<th>Mean age (Range)</th>
<th>Gender (M/F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 3</td>
<td>Phase 2, randomized, rater-blinded, active-comparator, multi-center</td>
<td>LEMTRADA Cycle 1, month 0: 12 mg/day for 5 days, OR 24 mg/day for 5 days Cycle 2, month 12 and Cycle 3, month 241: 12 mg/day for 3 days, OR 24 mg/day for 3 days Extension phase: further 3-day cycles (12 or 24 mg), optional or as needed IFNB-1a 44 mcg SC injections 3 times per week for 36 months</td>
<td>LEMTRADA 12 mg: 112 LEMTRADA 24 mg: 110 IFNB-1a: 111</td>
<td>LEMTRADA 12 mg: 31.9 years (18-49 years) LEMTRADA 24 mg: 32.2 years (18-54 years) IFNB-1a: 32.8 years (18-60 years)</td>
<td>LEMTRADA 12 mg: 35.7%/64.3% LEMTRADA 24 mg: 35.5%/64.5% IFNB-1a: 36.0%/64.0%</td>
</tr>
</tbody>
</table>

1 Cycle 3 at investigator’s discretion

Studies CAMMS223 and CAMMS323 were performed in treatment-naïve patients with active RRMS. Data from these studies were used only for assessment of safety.
Study Results

CAMMS32400507:

LEMTRADA met both co-primary endpoints.

The ARR was reduced by 49% in patients in the LEMTRADA 12 mg group as compared to SC IFNB-1a over 2 years (<0.0001). In addition, the risk of 6-month SAD was reduced by 42% over 2 years in patients treated with LEMTRADA (0.0084). Results are shown in Table 3.

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>LEMTRADA (N=426)</th>
<th>SC IFNB-1a (N=202)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relapse Rate (co-primary endpoint)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARR (95% CI)</td>
<td>0.26 (0.21, 0.33)</td>
<td>0.52 (0.41, 0.66)</td>
</tr>
<tr>
<td>Rate ratio (95% CI)</td>
<td>0.51 (0.39, 0.65)</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Disability (SAD ≥ 6 months; co-primary endpoint)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimate of patients with 6-month SAD (95% CI)</td>
<td>12.71 (9.89, 16.27)</td>
<td>21.13 (15.95, 27.68)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.58 (0.38, 0.87)</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>0.0084</td>
<td></td>
</tr>
</tbody>
</table>

Study CAMMS32400507 was open-label. More than half of the patients had their baseline EDSS assessed after randomization. 12.6% of patients in the interferon beta group and 2.3% in the alemtuzumab group dropped out of the trial prior to treatment resulting in an imbalance between the 2 arms of the study. When interpreting the efficacy results of the trial, these observations should be taken into consideration.
DETAILED PHARMACOLOGY

Pharmacokinetics

The pharmacokinetics, including information on the population PK, of LEMTRADA are described under ACTION AND CLINICAL PHARMACOLOGY.

There is a rapid disappearance of alemtuzumab from the systemic circulation in all patients, becoming undetectable by 1 month post-treatment in all patients. Clearance appears to be more rapid in patients with anti-alemtuzumab antibodies. The estimated T1/2α of alemtuzumab approximates 2 days and appears to be independent of cycle (i.e., lymphocyte count), anti-alemtuzumab antibody status, and dose level.

No effect of age, race or gender on PK of alemtuzumab was observed; however, the central volume of distribution was proportional to body weight. Both Cmax and AUC during cycle 1 are inversely correlated with weight. From the simple linear regression analyses, there appears to be a relationship between sex and Cmax.

Pharmacodynamics

The longitudinal pattern of lymphocyte depletion for the combined Phase 3 dataset was similar to that observed in the individual Phase 3 studies, with the lowest observed values seen at 1 month following each cycle, which was the first assessment after treatment. Data from Phase 2 suggest that lymphocyte nadir is reached within days of alemtuzumab administration. This agrees with the results of pilot studies which reported that lymphocyte depletion occurs within a day following administration of 12 mg alemtuzumab. In the Phase 2 study, lymphocyte counts had measurably risen by weeks 2 or 3, indicating that lymphocyte repopulation began as soon as serum alemtuzumab concentrations became low or undetectable.

Repopulation led to mean and median cell counts that were above the LLN within 12 months following any alemtuzumab treatment cycle for B lymphocytes, CD8+ T lymphocytes and NK cells, but not for CD4+ T lymphocytes. Longer follow-up from a limited number of patients in the Phase 2 study indicates that CD4+ cell repopulation is ongoing for several additional years.

While the absolute abundance of nearly all lymphocyte subsets was reduced by alemtuzumab treatment, differential depletion and repopulation led to shifts in the relative proportions of various lymphocyte subsets.

Lymphocyte depletion was consistently observed upon exposure or re-exposure to alemtuzumab, without correlation to Cmax or AUC. Overall, there appears to be no difference in lymphocyte depletion or repopulation across the exposure range evaluated following administration of 12 mg or 24 mg alemtuzumab.

No effect of age, race or gender on PD of alemtuzumab was observed.

TOXICOLOGY

Toxicology studies of alemtuzumab have been conducted using single IV dosing, as well as repeat dose regimens (i.e., cycle of administration) similar to that utilized in clinical studies in
MS. The nonclinical safety evaluation of LEMTRADA in animals has been limited to nonhuman primates and human CD52 transgenic mice, due to the requirement for both CD52 cross-reactivity and appropriate CD52 expression, which includes CD52 expression on lymphocytes and not erythrocytes, similar to that observed in humans. The affinity of LEMTRADA for CD52 in cynomolgus monkeys is approximately 10- to 16-fold less than for human CD52. Saturation of cynomolgus CD52 in vitro, and most likely in vivo, thus requires significantly greater concentrations of LEMTRADA than are required to saturate human CD52. Despite these experimental limitations, the toxicological studies conducted do nevertheless provide an informative profile of the activity of LEMTRADA in vivo.

Single dose and repeat dose toxicology studies were conducted in cynomolgus monkeys, using both IV and SC administrations of alemtuzumab at dose levels ranging from 0.1 to 30 mg/kg. The most consistent toxicologic effect in animal studies was lymphopenia, associated with the known mechanism of action of alemtuzumab.

Furthermore, reproductive and developmental toxicity studies were conducted in the huCD52 transgenic mouse to assess the effect of alemtuzumab on fertility in male and female mice; embryo-fetal development following gestational exposure; developmental and peri/postnatal effects following exposure during gestation or lactation; and developmental immunotoxicology following exposure during lactation. Effects on fertility and pregnancy following alemtuzumab were also identified and characterized, including a determination of the margin of safety based upon exposure.

Treatment with alemtuzumab IV at doses up to 10 mg/kg/day, administered for 5 consecutive days (AUC of 7.1 times the human exposure at the recommended daily dose) had no effect on fertility and reproductive performance in male mice.

In female mice dosed with alemtuzumab up to 10 mg/kg/day IV (AUC of 4.7 times the human exposure at the recommended daily dose) for 5 consecutive days prior to cohabitation with wild-type male mice, the average number of corpora lutea and implantation sites per mouse were significantly reduced as compared to vehicle treated animals. Reduced gestational weight gain relative to the vehicle controls was observed in pregnant mice dosed with 10 mg/kg/day. No other mating and fertility parameters were affected by doses of alemtuzumab as high as 10 mg/kg/day.

A reproductive toxicity study in pregnant mice exposed to IV doses of alemtuzumab up to 10 mg/kg/day (AUC 2.4 times the human exposure at the recommended dose of 12 mg/day) for 5 consecutive days during gestation resulted in significant increases in the number of dams with all conceptuses dead or resorbed, along with a concomitant reduction in the number of dams with viable fetuses. There were no external, soft tissue, or skeletal malformations or variations observed at doses up to 10 mg/kg/day.

Placental transfer and potential pharmacologic activity of alemtuzumab were observed during gestation and following delivery in mice. In studies in mice, alterations in lymphocyte counts were observed in pups exposed to alemtuzumab during gestation at doses of 3 mg/kg/day for 5
consecutive days (AUC 0.6 times the human exposure at the recommended dose of 12 mg/day). Cognitive, physical, and sexual development of pups exposed to alemtuzumab during lactation were not affected at doses up to 10 mg/kg/day. Lemtrada was detected in the milk and offspring of lactating female mice administered 10 mg/kg Lemtrada for 5 consecutive days postpartum.

There have been no studies to assess the carcinogenic or mutagenic potential of alemtuzumab.
REFERENCES


PART III: CONSUMER INFORMATION

LEMTTRA™ (alemtuzumab)

Concentrate for solution for intravenous infusion

This leaflet is part III of a three-part "Product Monograph" published when LEMTRADA (alemtuzumab) was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about LEMTRADA. Contact your doctor or pharmacist if you have any questions about the drug.

Keep this leaflet, Patient Guide and the Patient Alert Card. You should read them before starting LEMTRADA, and before each LEMTRADA treatment course.

- It is important that you keep the Card with you during treatment and for 48 months after the last dose of LEMTRADA, since side effects may occur even after you have stopped treatment.
- Show your Card and this package leaflet to any doctor involved in your treatment.

ABOUT THIS MEDICATION

What the medication is used for:
LEMTTRA is used to treat relapsing forms of multiple sclerosis (MS) in adults. LEMTRADA is recommended for MS patients who have not responded well to one or more of the other therapies (such as interferon beta) for multiple sclerosis.

Multiple sclerosis is a disease of the central nervous system (brain and spinal cord). In MS your immune system mistakenly attacks the protective layer (myelin) around the nerve fibres of your central nervous system, causing inflammation. When the inflammation causes you to have symptoms this is often called a "relapse" or "attack". In Relapsing Remitting MS (RRMS) patients experience relapses followed by periods of recovery.

The symptoms you experience depend on which part of your central nervous system is affected. The damage done to your nerves during this inflammation may be reversible, but as your disease progresses the damage may build up and become permanent.

What it does:
LEMTTRA is a monoclonal antibody. Monoclonal antibodies are proteins which bind to a unique site (called an antigen) on cells. LEMTRADA binds to an antigen, called CD52, which is present at high levels on certain cells of your immune system. LEMTRADA works on your immune system so that it may not attack your nervous system as much.

When it should not be used:
Do not use LEMTRADA if you have:
- An allergy to alemtuzumab or any of the other ingredients of LEMTRADA (see below for a list of important non-medicinal ingredients).
- Human Immunodeficiency Virus (HIV).
- Tuberculosis.
- Severe active infections.
- An active cancer.
- Have or had a type of rare infection of the brain called progressive multifocal leukoencephalopathy (PML).
- Or if you are using medications that weaken your immune system.

What the medicinal ingredient is:
The active substance is a monoclonal antibody called alemtuzumab.

What the important non-medicinal ingredients are:
The other ingredients in LEMTRADA are: dibasic sodium phosphate, disodium edetate dehydrate, potassium chloride, potassium dihydrogen phosphate, polysorbate 80, sodium chloride, water for injection.

What dosage forms it comes in:
LEMTTRA is provided as a concentrate solution that must be diluted prior to intravenous infusion. It is supplied in single-use vials containing 12 mg of alemtuzumab in 1.2 mL of sterile, preservative-free solution.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Autoimmune conditions
Serious and fatal autoimmune conditions including immune thrombocytopenic purpura (low platelets) and kidney disease have occurred in patients receiving LEMTRADA (see Autoimmune Side Effects, below).

Infections
Serious viral, bacterial, protozoan, and fungal infections including deaths have been reported in non-MS patients receiving alemtuzumab therapy (MabCampath®) at higher and more frequent doses than used in MS. Progressive multifocal leukoencephalopathy (PML) can occur as the result of a rare and serious brain infection. PML is a viral infection which causes serious illness or death. PML occurs in patients with leukemia with or without MabCampath treatment, and in patients treated with other MS treatments. Your doctor should monitor you for signs or symptoms of this and any infection. (see Infections, below)

Before using LEMTRADA tell your doctor if you:
- Are taking a medicine called MabCampath®.
- Have bleeding problems.
- Have thyroid problems.
- Have kidney problems.
• Have a recent history of infection, including tuberculosis.
• Have been vaccinated within 6 weeks before receiving a treatment course of LEMTRADA. After your treatment course with LEMTRADA, consult your doctor if you wish to be vaccinated. Your doctor will determine if it is safe for you to do so.
• Are pregnant or could become pregnant.
• Are breast-feeding or plan to breast-feed.
• Have or had cancer.

Pregnancy
If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. LEMTRADA is not recommended in pregnant women. Women who could become pregnant should use effective contraceptive methods during treatment with LEMTRADA and for 4 months after each course of treatment.

If you become pregnant after treatment with LEMTRADA and experience thyroid problems during pregnancy, extra caution is needed. Thyroid problems could be harmful to the baby (see Autoimmune Side Effects, below).

Breastfeeding
It is unknown if LEMTRADA can be transferred to a baby through breast milk, but there could be a risk. You should not breast-feed during each course of treatment with LEMTRADA or for 4 months after each treatment course.

LEMTTRA can cause serious side effects including:

Autoimmune side effects
Your body's immune system contains substances called antibodies that help fight infections. Autoimmune side effects are illnesses that occur when the body makes antibodies against itself. LEMTRADA may cause your body to develop antibodies that target certain organs, such as your thyroid. These antibodies may lead to development of autoimmune side effects such as immune thrombocytopenic purpura (ITP, or low platelets), thyroid disorders, or, in rare cases, kidney diseases. No one can predict who will develop an autoimmune side effect. Getting blood tests and knowing the symptoms can help with early diagnosis.

• Immune thrombocytopenic purpura (ITP, or low platelets):
LEMTTRA may cause a condition known as ITP, which results in a decrease in the number of platelets in the blood. Platelets are necessary for normal blood clotting. ITP can cause severe bleeding that, if untreated, may lead to serious health complications and possibly death. If detected early, ITP is usually treatable. Your doctor will order a blood test before starting LEMTRADA and on a monthly basis after your initial treatment course, and continuing for 4 years after your last LEMTRADA infusion. This blood test will help your doctor watch for changes in your platelet count in order to catch this side effect early. Importantly, ITP may also be detected by certain symptoms that you need to know (see “Serious Side Effects, How Often They Happen and What to Do About Them”, below). Call your doctor immediately if you have any of these signs or symptoms. If you cannot reach your doctor seek immediate medical attention.

• Thyroid disorders: The thyroid is a gland found in the front of the neck. This gland produces hormones that are important throughout your body. LEMTRADA may cause development of thyroid disorders, including an overactive or underactive thyroid gland. Thyroid disorders are generally treatable, though they may require lifelong treatment. Bulging of the eyes may occur with an overactive thyroid. Your doctor will order a blood test before starting LEMTRADA and every 3 months after your initial treatment course, and continuing for 4 years after your last LEMTRADA infusion. This blood test will help your healthcare provider detect thyroid disease early. See “Serious Side Effects, How Often They Happen and What to Do About Them”, below for signs and symptoms of thyroid disorders you should be aware of and what to do should they occur. Call your doctor if you have any of these signs or symptoms.

Talk to your doctor if you are considering becoming pregnant or if you become pregnant after receiving LEMTRADA, as untreated thyroid disease may cause harm to you or your developing baby.

• Kidney diseases: LEMTRADA may cause a condition known as anti-glomerular basement membrane disease. Anti-glomerular basement membrane disease is an autoimmune side effect that can result in severe damage to the kidneys. It can also damage the lungs, although this was not seen in clinical trials with LEMTRADA. If untreated, anti-glomerular basement membrane disease can cause kidney failure requiring chronic dialysis or transplant and may lead to death. Your healthcare provider will order a blood test and urine test before starting LEMTRADA and on a monthly basis after your initial treatment course, and continuing for 4 years after your last LEMTRADA infusion. Both of these tests will help your doctor watch for signs of kidney disease to help catch this side effect early. See “Serious Side Effects, How Often They Happen and What to Do About Them”, below for signs and symptoms of anti-glomerular basement membrane disease you should be aware of and what to do should they occur. If untreated it can cause kidney failure requiring dialysis or transplantation, and may lead to death. Call your doctor immediately if you have any of these signs or symptoms. If you cannot reach your doctor seek immediate medical attention.

• Other autoimmune conditions
Very rarely, patients have experienced autoimmune conditions with the red blood cells or white blood cells. This can be diagnosed from the blood checks that you will be having after LEMTRADA treatment. If you develop one of these conditions your doctor will take appropriate measures to treat it.
Serious infections
LEMTRADA is a medicine that lowers the number of some white blood cells in your blood for a period of time after treatment. These white blood cells generally return to normal levels over time. People with decreased white blood cells may have an increased risk for developing serious infections.

Serious infections may occur if you take LEMTRADA. See “Serious Side Effects, How Often They Happen and What to Do About Them”, below for signs and symptoms of serious infections you should be aware of and what to do should they occur.

You may need to go to the hospital for treatment if you develop a serious infection. It is important to tell the emergency personnel that you have received LEMTRADA. If you have signs or symptoms of an active infection, it is important that you tell your healthcare provider.

Infusion reactions
Most patients treated with LEMTRADA will experience side-effects at the time of the infusion or within 24 hours after the infusion. These reactions are described in “Side Effects and What to Do About Them” below.

Most infusion reactions are mild but some serious reactions are possible such as fever, hives, irregular heartbeat, nausea, chest discomfort or low blood pressure. Occasionally allergic reactions are possible.

To reduce these effects, your doctor will give you medication (corticosteroids) before the first 3 infusions of a treatment course. Other treatments to limit these reactions can also be given before the infusion or when you experience symptoms. In addition, you will be observed during the infusion and for at least 2 hours after the infusion has been completed in the clinic. You should know the symptoms of infusion reactions and keep checking for them for at least the first 24 hours after each LEMTRADA infusion. In case of serious reactions, it is possible that the infusion may be slowed down or even stopped.

INTERACTIONS WITH THIS MEDICATION

Interactions between LEMTRADA and other drugs have not been studied. Tell your doctor if you are taking, have recently taken, or might take any other medications, including vaccinations or medications taken without a prescription, such as vitamins and herbal medicines.

Besides LEMTRADA, there are other treatments (including those for MS, or to treat other conditions) which could affect your immune system and so could affect your ability to fight infections. If you have used another MS treatment in the past, your doctor may ask you to stop the other medicine in advance of starting treatment with LEMTRADA.

The safety of immunization with any vaccine, particularly live viral vaccines, following therapy with LEMTRADA has not been studied. It is unknown if LEMTRADA affects your ability to raise a response to a vaccine. If you have not completed the standard required vaccinations, your doctor will consider whether you should have them before your LEMTRADA treatment. In particular, your doctor will consider vaccinating you against chicken-pox. Any vaccination will need to be given to you at least 6 weeks prior to starting a LEMTRADA treatment course.

You must not receive live viral vaccines if you have recently received LEMTRADA.

PROPER USE OF THIS MEDICATION

LEMTRADA can only be prescribed by a doctor who is trained in treating neurological conditions. LEMTRADA will be prepared and given to you by a healthcare professional.

Usual dose:
LEMTRADA will be given to you as an infusion into a vein. Each infusion will take approximately 4 hours. For the first treatment course you will receive one infusion per day for 5 days (course 1). One year later you will receive one infusion per day for 3 days (course 2). Each infusion delivers 12 mg of LEMTRADA. There is no LEMTRADA treatment between the two courses.

Your doctor will order blood and urine tests, and an EKG before starting LEMTRADA. Blood and urine tests will continue for 4 years after your last LEMTRADA infusion. It is important to get this testing done according to the recommended schedule, in order for your healthcare provider to watch for signs of autoimmune side effects so that treatment can occur quickly, if needed.

Missed Dose:
If you miss a dose, consult with your doctor. More than one dose should not be given on the same day.

OVERDOSE

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, LEMTRADA can cause side effects.

Very common side effects (reported in at least 1 of every 10 patients in clinical trials) which often occur during or shortly after a single infusion or treatment course include:

- Headache, dizziness
- Rash, hives, itching
- Fever
- Nausea, vomiting
• Difficulty sleeping

Other very common side effects (reported in at least 1 of every 10 patients in clinical trials) experienced after a LEMTRADA treatment course include:
• Back pain, joint pain, pain in arms or legs
• Upper respiratory tract infection/cough, cold
• Urinary tract infection
• Chills
• Sore throat or mouth pain
• Feeling tired
• Bruising
• Tingling sensation
• Diarrhea

Other common side effects (reported between 5 and 10 of every 100 patients in clinical trials) include:
• Decrease of white blood cells (lymphocytes)
• Fast or irregular heartbeat (palpitations), chest discomfort
• Indigestion (heartburn), stomach pain, constipation
• Flu, flu-like illness
• Muscular pain, muscular weakness, muscle spasms, neck pain
• Swelling of the arms and/or legs
• Weakness
• Oral herpes
• Altered taste, numbness, blurred vision
• Depression, anxiety
• Cough, difficulty breathing or shortness of breath
• Bronchitis
• Body rash, redness of the skin
• Reddening of the face and neck
• Under-active thyroid gland
• Nose bleeds

LEMTTRA may cause serious side effects, including autoimmune side effects and serious infections (see “WARNINGS and PRECAUTIONS” above for additional information.

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Thyroid disorders: Symptoms including:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Common</td>
<td>• Excessive sweating</td>
</tr>
<tr>
<td>(occurring in at least 1 of every 10 patients)</td>
<td>• Unexplained weight loss</td>
</tr>
<tr>
<td></td>
<td>• Eye swelling</td>
</tr>
<tr>
<td></td>
<td>• Nervousness</td>
</tr>
<tr>
<td></td>
<td>• Fast heartbeat</td>
</tr>
<tr>
<td></td>
<td>• Unexplained weight gain,</td>
</tr>
<tr>
<td></td>
<td>• Feeling cold</td>
</tr>
<tr>
<td></td>
<td>• Worsening tiredness</td>
</tr>
<tr>
<td></td>
<td>• Constipation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Immune thrombocytopenic purpura (ITP): Symptoms, including:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Easy bruising</td>
</tr>
<tr>
<td>• Bleeding from a cut that is hard to stop</td>
</tr>
<tr>
<td>• Heavier menstrual periods than normal</td>
</tr>
<tr>
<td>• Bleeding from your gums or nose</td>
</tr>
<tr>
<td>• Small, scattered spots on your skin that are red, pink, or purple</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Uncommon</th>
<th>Kidney disease: Symptoms including:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(occurring between 1 and 10 of every 1000 patients)</td>
<td>• Blood in urine (red or tea-colored urine)</td>
</tr>
<tr>
<td></td>
<td>• Swelling in your legs or feet</td>
</tr>
<tr>
<td></td>
<td>• Coughing up blood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Common</th>
<th>Serious infections: Symptoms including:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(occurring between 1 and 10 of every 100 patients)</td>
<td>• Fever</td>
</tr>
<tr>
<td></td>
<td>• Chills</td>
</tr>
<tr>
<td></td>
<td>• Swollen glands</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking LEMTRADA contact your doctor.
HOW TO STORE IT

LEMTRADA must be refrigerated (2º to 8ºC) and protected from light. Do not freeze or shake. Do not use after the expiration date on the vial and outer carton.

LEMTRADA contains no preservatives. LEMTRADA should be used within 8 hours after dilution. During that time, the diluted solution may be stored at room temperature (15º to 25ºC) or in a refrigerator (2º to 8ºC), and must be protected from light.

Reporting Suspected Side Effects

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to:
    - Canada Vigilance Program
    - Health Canada
    - Postal Locator 0701D
    - Ottawa, Ontario
    - K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:
http://www.genzyme.ca

or by contacting the sponsor, Genzyme Canada, a division of sanofi-aventis Canada Inc. at:
1-855-671-2663

This leaflet was prepared by Genzyme Canada, a division of sanofi-aventis Canada Inc.

Last revised: 12 December 2013